Therapeutic anticancer neoepitope vaccine
AssigneeNykode Therapeutics ASA
InventorsStine Granum, Elisabeth Stubsrud, Agnete Brunsvik Fredriksen
Life of this patent
Estimating the term…
Abstract
The present invention relates to an anticancer vaccine which includes polynucleotides or polypeptides, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine. The vaccine includes a polynucleotide with a nucleotide sequence encoding a targeting unit, a dimerization unit, a first linker and an antigenic unit. The antigenic unit includes from 3 to 50 antigenic subunits separated by a second linker with each antigenic subunit having at least a part of a cancer neoepitope sequence. The vaccine can include a polypeptide encoded by the polynucleotide or a dimeric protein with two polypeptides encoded by the polynucleotide.
Claims19
An anticancer neoepitope composition comprising:
- a DNA polynucleotide encoding a polypeptide comprising:
- a targeting unit,
- a dimerization unit,
- a first linker, and
- an antigenic unit having n cancer neoepitope sequences, wherein the antigenic unit is comprised of n−1 antigenic subunits, each subunit comprising a cancer neoepitope sequence having a length of 7 to 30 amino acids and a second linker;
- wherein n is an integer of from 10 to 20.
Dependencies are inferred from the claim text.